Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Codeine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 9/20 | 1.00 |
| ▸ | OPRM1 known ✓ | P35372 | 7/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 5/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.76 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.76 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Codeine SCHEMBL1276342 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL10329428 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL16922140 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL8218174 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL13696342 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL3257 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL1560699 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL14371354 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL21077535 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Codeine SCHEMBL16922135 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9827239-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2017-04-27 | — | — | US | disclosed |
| EP-2628489-B1 | PEG oligomer-fentanyl conjugates | NEKTAR THERAPEUTICS (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2170898-B1 | METHODS FOR N-DEMETHYLATION OF MORPHINE AND TROPANE ALKALOIDS | UNIV BROCK (CA) | 2016-05-04 | — | — | EP | disclosed |
| US-9233167-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150238624-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2015-08-27 | — | — | US | disclosed |
| US-7935820-B2 | Methods for N-demethylation of morphine and tropane alkaloids | BROCK UNIVERSITY (CA) | 2011-05-03 | — | — | US | disclosed |
| US-7935820-B2 | Methods for N-demethylation of morphine and tropane alkaloids | BROCK UNIVERSITY (CA) | 2011-05-03 | — | — | US | disclosed |
| US-7928234-B2 | Conversion of thebaine to morphine derivatives | BROCK UNIVERSITY (CA) | 2011-04-19 | — | — | US | disclosed |
| WO-2009003272-A1 | METHODS FOR N-DEMETHYLATION OF MORPHINE AND TROPANE ALKALOIDS | BROCK UNIVERSITY (CA) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005564-A1 | METHODS FOR N-DEMETHYLATION OF MORPHINE AND TROPANE ALKALOIDS | BROCK UNIVERSITY | 2009-01-01 | — | — | US | disclosed |
| US-20090005564-A1 | METHODS FOR N-DEMETHYLATION OF MORPHINE AND TROPANE ALKALOIDS | BROCK UNIVERSITY | 2009-01-01 | — | — | US | disclosed |
| US-20090005563-A1 | CONVERSION OF THEBAINE TO MORPHINE DERIVATIVES | BROCK UNIVERSITY | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRD1 5/4885OPRM1 1/4885OPRK1 3/4885 |
| US-20090005564-A1 | METHODS FOR N-DEMETHYLATION OF MORPHINE AND TROPANE ALKALOIDS | HNMT, NNMT, PNMT | OPRD1 14/4885OPRM1 4/4885OPRK1 12/4885 |
| US-20150238624-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | OPRD1 5/4885OPRM1 1/4885OPRK1 3/4885 |
| US-20090005563-A1 | CONVERSION OF THEBAINE TO MORPHINE DERIVATIVES | OPRK1, OPRM1, OPRD1 | OPRD1 3/4885OPRM1 2/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.